Inhibitors of pro-HGF activation overcome resistance to anti-EGFR therapy

September 16th, 2019 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics, and Co-Founder of ProteXase Therapeutics, Inc., along with Lidija Klampfer, PhD, Co-Founder and Chief Scientific Officer of ProteXase Therapeutics, Inc., received a one-year SBIR grant award from the National Cancer Institute for their research entitled “Inhibitors of pro-HGF activation overcome resistance to anti-EGFR therapy”.